RecruitingNCT05770375
Safety and tolerability of MDMA in people with schizophrenia
About this title
Read the official source — NCT05770375Medication studyAges 18–60United States
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
- Listed locations
- Los AngelesSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 1, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 20
- Sponsor
- Anya Bershad, MD, PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT05770375
- Official title
Show the full official title
Tolerability of MDMA in Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Los Angeles
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Anya Bershad, MD, PhD.
Does this study involve medication?
Yes. The study involves medication, including MDMA 40mg, MDMA 80mg and MDMA 120mg.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
